Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.45
  • Today's Change-0.02 / -0.58%
  • Shares traded216.00k
  • 1 Year change+208.04%
  • Beta2.1833
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

  • Revenue in HKD (TTM)95.43m
  • Net income in HKD-258.61m
  • Incorporated2018
  • Employees152.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kintor Pharmaceutical Ltd12.43m-189.00m1.37bn136.00--5.04--110.36-0.437-0.4370.02870.54610.019410.661.0673,966.23-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Wuhan YZY Biopharma Co Ltd164.04m-88.28m1.40bn106.00------8.56-0.4554-0.45540.8462-0.16020.580511.5413.961,451,683.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
HighTide Therapeutics Inc0.00-329.39m1.45bn57.00--3.65-----0.7286-0.72860.000.69340.00----0.00-49.50---63.55--------------0.2129------59.35------
Immunotech Biopharm Ltd0.00-252.85m1.57bn173.00---------0.4518-0.45180.00-0.28780.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
Cloudbreak Pharma Inc78.15m-326.93m1.92bn60.00------24.58-0.3897-0.38970.0932-3.08------1,532,373.00-------------418.33------19.44------23.40------
ImmuneOnco Biopharmaceuticls Shanghi Inc126.82m-342.43m1.96bn195.00--3.06--15.48-0.8705-0.87050.32211.480.148--3,865.48812,941.60-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Mabpharm Ltd479.59m-31.09m2.10bn383.00--18.8157.034.39-0.0076-0.00760.11630.02710.42090.46594.051,522,523.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Jiangsu Recbio Technology Co Ltd12.33m-739.77m2.17bn507.00--10.61--176.26-1.55-1.550.02580.42420.006----23,220.65-36.26-31.31-64.03-37.31-----5,990.59--0.2767-100.740.8254------1.67--16.82--
Frontage Holdings Corp1.98bn29.97m2.20bn1.54k73.120.82386.991.110.01480.01480.97351.310.454560.363.971,267,499.000.69023.050.86543.6427.7832.141.526.841.221.970.28610.00-1.9020.48-92.68-46.7213.29--
Antengene Corp Ltd95.43m-258.61m2.34bn152.00--2.70--24.56-0.4162-0.41620.15361.280.06191.513.20564,671.80-16.77-48.14-19.52-53.0678.54---271.00-1,460.934.41--0.2346--36.62--45.07--259.46--
Hanx Biopharmaceuticals (Wuhan) Co Ltd-100.00bn-100.00bn2.62bn-------------------------------------------------------52.30------
Clover Biopharmaceuticals Ltd58.57m-1.03bn2.86bn243.00------48.76-0.8194-0.81940.0466-1.490.04330.054747.89195,238.00-76.07-75.37---188.1462.57---1,756.85-13,419.000.2541-------2.13---552.11---24.90--
BioDlink International Co Ltd1.21bn8.21m3.25bn604.00370.883.9235.552.690.01130.01131.661.070.72752.355.491,975,381.000.495-11.370.6586-14.8971.1073.140.6805-24.911.681.830.3519--40.7089.20192.05--27.04--
Hua Medicine419.33m1.22bn3.30bn285.002.552.562.627.861.231.230.42481.220.24111.765.712,496,030.0069.99-21.8382.64-25.3152.55--290.30-395.247.00--0.2038--234.02---18.42---17.81--
Data as of Feb 16 2026. Currency figures normalised to Antengene Corp Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

1.42%Per cent of shares held by top holders
HolderShares% Held
Templeton Asset Management Ltd. (Hong Kong)as of 31 Dec 20253.90m0.57%
Janus Henderson Investors (Singapore) Ltd.as of 31 Dec 20252.02m0.30%
SSgA Funds Management, Inc.as of 05 Feb 20261.69m0.25%
Janus Henderson Investors UK Ltd.as of 31 Dec 20251.13m0.17%
Dimensional Fund Advisors LPas of 30 Nov 2025846.00k0.13%
Templeton Asset Management Ltd.as of 31 Dec 202562.50k0.01%
Norges Bank Investment Managementas of 30 Jun 20250.000.00%
China Universal Asset Management Co., Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.